Unlock stock picks and a broker-level newsfeed that powers Wall Street.
ASX - Delayed Quote AUD

Neuren Pharmaceuticals Limited (NEU.AX)

Compare
10.81
-0.54
(-4.76%)
At close: 4:10:06 PM GMT+11
Loading Chart for NEU.AX
  • Previous Close 11.35
  • Open 11.38
  • Bid 10.81 x --
  • Ask 10.82 x --
  • Day's Range 10.75 - 11.48
  • 52 Week Range 10.75 - 24.00
  • Volume 920,311
  • Avg. Volume 555,788
  • Market Cap (intraday) 1.467B
  • Beta (5Y Monthly) 2.08
  • PE Ratio (TTM) 9.92
  • EPS (TTM) 1.09
  • Earnings Date Feb 28, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 24.97

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Camberwell, Australia.

www.neurenpharma.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NEU.AX

View More

Performance Overview: NEU.AX

Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

NEU.AX
13.52%
S&P/ASX 200 [XJO] (^AXJO)
2.75%

1-Year Return

NEU.AX
47.01%
S&P/ASX 200 [XJO] (^AXJO)
1.95%

3-Year Return

NEU.AX
174.37%
S&P/ASX 200 [XJO] (^AXJO)
5.88%

5-Year Return

NEU.AX
970.30%
S&P/ASX 200 [XJO] (^AXJO)
56.58%

Compare To: NEU.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NEU.AX

View More

Valuation Measures

Annual
As of 4/1/2025
  • Market Cap

    1.47B

  • Enterprise Value

    1.24B

  • Trailing P/E

    10.45

  • Forward P/E

    66.67

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.96

  • Price/Book (mrq)

    4.03

  • Enterprise Value/Revenue

    5.84

  • Enterprise Value/EBITDA

    7.09

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    65.51%

  • Return on Assets (ttm)

    34.05%

  • Return on Equity (ttm)

    49.92%

  • Revenue (ttm)

    216.83M

  • Net Income Avi to Common (ttm)

    142.04M

  • Diluted EPS (ttm)

    1.09

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    222.24M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -42.25M

Research Analysis: NEU.AX

View More

Company Insights: NEU.AX

Research Reports: NEU.AX

View More

People Also Watch